Epidermal growth factor receptor inhibitors in lung cancer therapy

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue SUPP. 1, 2004, Pages 17-27

  Laskin, Janessa J ^a   Sandler, Alan B ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); IMC C225; Non small cell lung cancer (NSCLC); OSI 774; Tyrosine kinase inhibitors; ZD1839

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MATUZUMAB; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACNE; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG RECEPTOR BINDING; DRUG TARGETING; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LUNG CANCER; MULTIMODALITY CANCER THERAPY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 3042818491     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829641     Document Type: Review

References (72)

1. Johnson DH. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience. Chest 2000;117:S133-S137
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98
3. Anonymous. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909
4. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Cancer 1995;76:593-601
5. Shepherd FA. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol 1999;26:3-11
6. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194
7. Dranitsaris G, Cottrell W, Evans WK. Cost-effectiveness of chemotherapy for non-small-cell lung cancer. Curr Opin Oncol 2002;14:375-383
8. Medley L, Cullen M. Best supportive care versus palliative chemotherapy in non-small-cell lung cancer. Curr Opin Oncol 2002;14:384-388
9. Paesmans M. Benefits of chemotherapy for quality of life in patients with advanced non-small-cell lung cancer. Curr Opin Oncol 2002;14:389-393
10. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72
11. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103
12. Gridelli C, Perrone F, Nelli F, et al. Quality of life in lung cancer patients. Ann Oncol 2001;12(suppl 3):S21-S25
13. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763
14. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-250
15. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
16. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29:27-36
17. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(suppl 4):S3-S8
18. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001;13:491-498
19. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002;29(suppl 4):S47-S50
20. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:2379-2385
21. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-522
22. Rusch V, Klimstra D, Linkov I, et al. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 1995;55:1365-1372
23. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(suppl 4):S9-S15
24. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long-term survival. Br J Cancer 1993;68:162-165
25. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998;77:663-669
26. Dumez H, Hoekstra R, Eskens F, et al. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally three times a week to patients with advanced cancer [abstract 341]. Proc Am Soc Clin Oncol 2002;21:86a
27. Murren JR, Papadimitrakopoulou VA, Sizer KC, et al. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers [abstract 377]. Proc Am Soc Clin Oncol 2002;21:95a
28. Hoekstra R, Dumez H, van Oosterom AT, et al. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer [abstract 340]. Proc Am Soc Clin Oncol 2002;21:86a
29. Forero L, Patnaik A, Hammond LA, et al. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin [abstract 1908]. Proc Am Soc Clin Oncol 2002;21:25b
30. Goss GD, Hirte H, Lorimer I, et al. Final results of the dose escalation phase of a phase I pharmacokinetics (PK), pharmacodynamic (PD) and biological activity study of ZD1839: NCIC CTG Ind.122 [abstract 355]. Proc Am Soc Clin Oncol 2001;20:85a
31. Negoro S, Nakagawa K, Fukuoka M, et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ("Iressa") in Japanese patients with various solid tumours [abstract 1292]. Proc Am Soc Clin Oncol 2001;20:324a
32. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract 1235]. Proc Am Soc Clin Oncol 2001;20:310a
33. Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability [abstract 686]. Proc Am Soc Clin Oncol 2000;19:177a
34. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-2250
35. Ferry D, Hammond L, Ranson M, et al. Intermittent oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study [abstract 5E]. Proc Am Soc Clin Oncol 2000;19:3a
36. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract 1166]. Proc Am Soc Clin Oncol 2002;21:292a
37. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246
38. Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 2001;12:1667-1670
39. Douillard J-Y, Giaccone G, Horai T, et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ("Iressa") (IDEAL 1) [abstract 1195]. Proc Am Soc Clin Oncol 2002;21:299a
40. Natale RB, Skarin AT, Maddox A-M, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ("Iressa") in IDEAL 2 [abstract 1167]. Proc Am Soc Clin Oncol 2002;21:292a
41. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279
42. Garrison MA, Tolcher A, McCreery H, et al. A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors [abstract 283]. Proc Am Soc Clin Oncol 2001;20:72a
43. Rinehart JJ, Wilding G, Willson J, et al. A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors [abstract 41]. Proc Am Soc Clin Oncol 2002;1:11a
44. Shin DM, Nemunaitis J, Zinner RG, et al. A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors [abstract 324]. Proc Am Soc Clin Oncol 2001;20:82a
45. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063
46. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892
47. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997;89:341-343
48. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-2707
49. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000;60:25-32
50. Miller VA, Johnson D, Heelan RT, et al. A pilot trial demonstrates the safety of ZD1839 ("Iressa"), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC) [abstract 1301]. Proc Am Soc Clin Oncol 2001;20:326a
51. Gonzalez-Larriba JL, Giaccone G, van Oosterom A, et al. ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours: final results of a phase I trial [abstract 376]. Proc Am Soc Clin Oncol 2002;21:95a
52. Herbst RS, Giaccone G, Schiller J, et al. Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy (CT) for advanced non-small-cell lung cancer (NSCLC) [abstract 2523]. Proc Am Soc Clin Oncol 2003;22:627
53. Giaccone G, Johnson D, Scagliotti GV, et al. Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2) [abstract 2522]. Proc Am Soc Clin Oncol 2003;22:627
54. Forouzesh B, Hidalgo M, Takimoto C, et al. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel [abstract 81]. Proc Am Soc Clin Oncol 2002;21:21a
55. Ratain MJ, George CM, Janisch L, et al. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors [abstract 2115]. Proc Am Soc Clin Oncol 2002;21:76b
56. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-1465
57. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001;1:719-732
58. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-914
59. Falcey J, Pfister D, Cohen R, et al. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas [abstract 1364]. Proc Am Soc Clin Oncol 1997;16:383a
60. Kim ES, Mauer AM, Fossella FV, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC) [abstract 1168]. Proc Am Soc Clin Oncol 2002;21:293a
61. Tewes M, Schleucher N, Dirsch O, et al. Results of a phase I trial of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors [abstract 378]. Proc Am Soc Clin Oncol 2002;21:95a
62. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-1243
63. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23
64. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000;60(suppl 1):S15-S23
65. Franklin WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002;29(suppl 4):S3-S14
66. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 2002;20:2217-2219
67. Chen X, Yeung TK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000;277:757-763
68. Chakravarti A, Chakladar A, Delaney MA, et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002;62:4307-4315
69. Ling YH, Donato NJ, Perez-Soler R. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemother Pharmacol 2001;47:473-480
70. Donato NJ, Perez M, Kang H, et al. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res 2000;6:193-202
71. Perez M, Donato NJ. Activation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor correlates with loss of cytotoxic activity. J Interferon Cytokine Res 1996;16:307-314
72. Ferreira CG, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002;41:57-77